Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 25.40
-0.15 (-0.59%)
May 8, 2026, 1:44 PM CST
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.51 billion as of May 8, 2026. Its market cap has increased by 32.98% in one year.
Market Cap
1.51B
Enterprise Value
1.38B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
25.40
Market Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.51B, an increase of 30.16%. That is a compound annual growth rate of 3.60%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 8, 2026 | 1.51B | -9.45% |
| Dec 31, 2025 | 1.67B | 36.50% |
| Dec 31, 2024 | 1.22B | -9.95% |
| Dec 29, 2023 | 1.36B | -8.36% |
| Dec 30, 2022 | 1.48B | -38.27% |
| Dec 30, 2021 | 2.40B | 63.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 25, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anti-Microbial Savior BioteQ | 1.90B |
| TaiRx | 1.86B |
| Greenyn Biotechnology | 1.85B |
| Andros Pharmaceuticals Co.,Ltd | 1.82B |
| Great Novel Therapeutics Biotech & Medicals | 1.69B |
| GenMont Biotech Incorporation | 1.51B |
| NeoCore Technology | 1.40B |
| Enimmune | 1.37B |